HC Wainwright Has Strong Estimate for GLUE FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Monte Rosa Therapeutics to a loss of $1.30 per share from a projected loss of $1.81, maintaining a Buy rating and $25 price target.
• Monte Rosa reported quarterly EPS of $0.03, beating the consensus estimate of a $0.21 loss, while revenue of $54.37 million exceeded the $33.87 million forecast.
• Analysts’ average rating is Moderate Buy, with an average price target of $26.44; shares opened at $10.58, below the target estimates.

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Investment analysts at HC Wainwright upped their FY2026 EPS estimates for shares of Monte Rosa Therapeutics in a note issued to investors on Friday, November 6th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($1.30) per share for the year, up from their previous estimate of ($1.81). HC Wainwright has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for Monte Rosa Therapeutics' current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Monte Rosa Therapeutics' Q4 2026 earnings at ($0.49) EPS, Q2 2027 earnings at ($0.55) EPS and FY2027 earnings at ($2.23) EPS.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.24. Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%. The firm had revenue of $54.37 million during the quarter, compared to the consensus estimate of $33.87 million.

A number of other analysts have also issued reports on the stock. Raymond James Financial set a $25.00 price target on shares of Monte Rosa Therapeutics in a research report on Monday, October 5th. Wells Fargo & Company lowered their price objective on shares of Monte Rosa Therapeutics from $27.00 to $25.00 and set an "overweight" rating on the stock in a research report on Friday. UBS Group started coverage on shares of Monte Rosa Therapeutics in a research report on Sunday, October 11th. They set a "buy" rating and a $19.00 price objective on the stock. Guggenheim reiterated a "buy" rating and issued a $28.00 target price on shares of Monte Rosa Therapeutics in a research report on Tuesday, August 25th. Finally, JPMorgan Chase & Co. cut their target price on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an "overweight" rating for the company in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $26.44.

Monte Rosa Therapeutics Price Performance

NASDAQ:GLUE opened at $10.58 on Tuesday. Monte Rosa Therapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $25.77. The stock's 50-day moving average is $11.65 and its two-hundred day moving average is $17.02. The stock has a market cap of $902.58 million, a PE ratio of -7.56 and a beta of 1.40.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. AlphaCentric Advisors LLC lifted its holdings in shares of Monte Rosa Therapeutics by 112.0% during the 3rd quarter. AlphaCentric Advisors LLC now owns 26,802 shares of the company's stock valued at $320,000 after buying an additional 14,157 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Monte Rosa Therapeutics in the third quarter worth approximately $52,000. Profund Advisors LLC raised its position in Monte Rosa Therapeutics by 7.6% during the third quarter. Profund Advisors LLC now owns 32,406 shares of the company's stock valued at $387,000 after acquiring an additional 2,295 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Monte Rosa Therapeutics by 14.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 17,166 shares of the company's stock valued at $202,000 after acquiring an additional 2,121 shares in the last quarter. Finally, Sterling Capital Management LLC raised its position in Monte Rosa Therapeutics by 842.3% during the third quarter. Sterling Capital Management LLC now owns 2,450 shares of the company's stock valued at $29,000 after acquiring an additional 2,190 shares in the last quarter. 79.96% of the stock is owned by hedge funds and other institutional investors.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments.

The company's research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.